AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates
ZacksFebruary 14, 2020, 2:21 PM UTC. AstraZeneca AZN reported dismal fourth-quarter results with earnings and sales both missing the Zacks Consensus Estimate. Fourth-quarter 2019 core earnings of 45 cents per American depositary share missed the Zacks Consensus Estimate of 53 cents. Among the newer medicines, Lynparza sales rose 69% year over year and 7.3% sequentially to $351 million in the quarter on the back of expanded use in ovarian and breast cancer, as well as solid growth in emerging markets. AstraZeneca markets Lynparza in partnership with Merck MRK. Sales of other legacy drugs including Zoladex, Arimidex, Atacand and Daliresp/Daxas grew in the quarter while sales of others like Faslodex, Casodex, and Synagis declined.